Chemocentryx (CCXI) Holder Fosun International LTD Lowered Its Stake as Shares Rose; Diplomat Pharmacy Reg (DPLO) Market Valuation Declined While Rhenman & Partners Asset Management Ab Has Increased Its Holding

ChemoCentryx, Inc. (NASDAQ:CCXI) Logo

Fosun International Ltd decreased its stake in Chemocentryx Inc (CCXI) by 36.51% based on its latest 2018Q4 regulatory filing with the SEC. Fosun International Ltd sold 58,074 shares as the company’s stock rose 6.99% with the market. The institutional investor held 100,976 shares of the health care company at the end of 2018Q4, valued at $1.06 million, down from 159,050 at the end of the previous reported quarter. Fosun International Ltd who had been investing in Chemocentryx Inc for a number of months, seems to be less bullish one the $717.05 million market cap company. It closed at $13.64 lastly. It is down 12.22% since April 11, 2018 and is uptrending. It has outperformed by 7.85% the S&P500. Some Historical CCXI News: 23/05/2018 – ChemoCentryx Announces Two Upcoming Presentations at the 55th ERA-EDTA Congress; 09/05/2018 – ChemoCentryx 1Q Loss/Shr 19c; 22/03/2018 – ChemoCentryx Publishes Novel Findings of Role of CCR2 in Kidney Glomerulus, Supporting Advancement of CCR2 Inhibitor CCX140 in the Treatment of Focal Segmental Glomerulosclerosis (FSGS); 09/03/2018 – CHEMOCENTRYX SEES 2018 CASH & INVESTMENTS USE $65M-$75M; 09/05/2018 – CHEMOCENTRYX INC – QTRLY DILUTED NET LOSS PER COMMON SHARE $0.19; 09/03/2018 – ChemoCentryx Expects to Utilize Between $65M-$75M Cash and Investments in FY18; 09/05/2018 – CHEMOCENTRYX INC – EXPECTS TO UTILIZE CASH AND INVESTMENTS BETWEEN $65 MLN AND $75 MLN FOR TWELVE MONTHS ENDING DECEMBER 31, 2018; 09/03/2018 ChemoCentryx 4Q EPS 80c; 13/03/2018 – CHEMOCENTRYX INC CCXI.O : JP MORGAN RAISES TARGET PRICE TO $16 FROM $13; 09/03/2018 – CCXI PLANS TO START DEVT AVACOPAN IN HIDRADENITIS SUPPURATIVA

Rhenman & Partners Asset Management Ab increased its stake in Diplomat Pharmacy Inc Reg (DPLO) by 2.47% based on its latest 2018Q4 regulatory filing with the SEC. Rhenman & Partners Asset Management Ab bought 28,994 shares as the company’s stock declined 61.15% while stock markets rallied. The institutional investor held 1.20 million shares of the health care company at the end of 2018Q4, valued at $16.20 million, up from 1.17M at the end of the previous reported quarter. Rhenman & Partners Asset Management Ab who had been investing in Diplomat Pharmacy Inc Reg for a number of months, seems to be bullish on the $427.32 million market cap company. The stock increased 0.70% or $0.04 during the last trading session, reaching $5.74. About 1.10 million shares traded. Diplomat Pharmacy, Inc. (NYSE:DPLO) has declined 69.53% since April 11, 2018 and is downtrending. It has underperformed by 73.90% the S&P500. Some Historical DPLO News: 08/03/2018 – DANCE BIOPHARM ELECTS BENJAMIN WOLIN TO BOARD OF DIRECTORS; 07/05/2018 – Diplomat Pharmacy Backs 2018 Adj EPS 87c-Adj EPS 97c; 08/05/2018 – Diplomat Pharmacy’s Park Will Remain Director; 08/05/2018 – DIPLOMAT – ATUL KAVTHEKAR, CFO OF DIPLOMAT, WILL TEMPORARILY ASSUME ADDITIONAL RESPONSIBILITIES OF CEO UNTIL APPOINTMENT OF NEW CEO IS EFFECTIVE; 07/05/2018 – Diplomat Pharmacy 1Q Adj EPS 20c; 07/05/2018 – DIPLOMAT PHARMACY INC – REITERATE 2018 FINANCIAL OUTLOOK; 15/05/2018 – Diplomat Pharmacy, Inc.: Brian Griffin Appointed CEO, Chairman of the Board; 07/05/2018 – Diplomat Pharmacy Raises 2018 View To Rev $5.5B-$5.9B; 08/05/2018 – Diplomat Pharmacy in Final Stages of CEO Search Process; 10/05/2018 – DIPLOMAT PHARMACY INC – BOARD WILL EXPAND TO EIGHT MEMBERS WITH GRIFFIN’S APPOINTMENT

Since October 16, 2018, it had 0 insider buys, and 8 selling transactions for $87.64 million activity. $332,779 worth of ChemoCentryx, Inc. (NASDAQ:CCXI) was sold by Cappel Markus J.. $457,747 worth of ChemoCentryx, Inc. (NASDAQ:CCXI) shares were sold by KANAYA SUSAN M. Shares for $447,092 were sold by Schall Thomas J. on Thursday, January 10.

Fosun International Ltd, which manages about $1.67B US Long portfolio, upped its stake in Immunomedics Inc (NASDAQ:IMMU) by 160,000 shares to 235,433 shares, valued at $3.58M in 2018Q4, according to the filing. It also increased its holding in Boeing Co (NYSE:BA) by 2,195 shares in the quarter, for a total of 3,050 shares, and has risen its stake in Garmin Ltd (NASDAQ:GRMN).

Investors sentiment decreased to 0.93 in 2018 Q4. Its down 0.05, from 0.98 in 2018Q3. It worsened, as 7 investors sold CCXI shares while 38 reduced holdings. 18 funds opened positions while 24 raised stakes. 27.13 million shares or 1.23% more from 26.80 million shares in 2018Q3 were reported. Her Majesty The Queen In Right Of The Province Of Alberta As Represented By Alberta Inv Mgmt holds 0% or 37,000 shares. Landscape Mgmt Limited Liability Company holds 0.01% or 10,285 shares in its portfolio. Bancorporation Of Montreal Can holds 129,083 shares or 0% of its portfolio. Strs Ohio invested in 0% or 55,800 shares. Gsa Prtnrs Llp holds 107,800 shares or 0.14% of its portfolio. Voya Inv Mgmt Limited Company holds 0% or 10,588 shares in its portfolio. Citadel Ltd Limited Liability Company invested in 19,773 shares. Bancorp Of America Corporation De owns 93,623 shares. Adams Diversified Equity Fund, a Maryland-based fund reported 38,600 shares. Goldman Sachs Group Inc Incorporated holds 0% or 215,812 shares. Trexquant Investment LP accumulated 0.02% or 33,717 shares. Millennium Mgmt Ltd Liability Corp holds 0% or 16,813 shares in its portfolio. 1.22M were accumulated by Carmignac Gestion. Panagora Asset Mgmt reported 324,223 shares. Fosun Limited stated it has 100,976 shares.

More notable recent ChemoCentryx, Inc. (NASDAQ:CCXI) news were published by: Benzinga.com which released: “52 Biggest Movers From Yesterday – Benzinga” on March 26, 2019, also Benzinga.com with their article: “71 Biggest Movers From Yesterday – Benzinga” published on March 28, 2019, Benzinga.com published: “10 Biggest Price Target Changes For Wednesday – Benzinga” on March 27, 2019. More interesting news about ChemoCentryx, Inc. (NASDAQ:CCXI) were released by: Benzinga.com and their article: “60 Stocks Moving In Wednesday’s Mid-Day Session – Benzinga” published on March 27, 2019 as well as Globenewswire.com‘s news article titled: “ChemoCentryx Appoints Rita Jain, M.D. to Board of Directors – GlobeNewswire” with publication date: March 28, 2019.

Rhenman & Partners Asset Management Ab, which manages about $874.81M US Long portfolio, decreased its stake in Vertex Pharmaceuticals Inc (NASDAQ:VRTX) by 10,040 shares to 132,425 shares, valued at $21.94 million in 2018Q4, according to the filing. It also reduced its holding in Alkermes Plc (NASDAQ:ALKS) by 127,211 shares in the quarter, leaving it with 174,399 shares, and cut its stake in Agios Pharmaceuticals Inc (NASDAQ:AGIO).

More notable recent Diplomat Pharmacy, Inc. (NYSE:DPLO) news were published by: Businesswire.com which released: “INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Diplomat Pharmacy, Inc. Investors – Business Wire” on March 22, 2019, also Globenewswire.com with their article: “CLASS ACTION UPDATE for TYME, KHC, DPLO and CTL: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders – GlobeNewswire” published on March 20, 2019, Globenewswire.com published: “Bragar Eagel & Squire, PC Reminds Investors That Class Action Lawsuits Have Been Filed Against Health Insurance, Conagra, Kraft Heinz, and Diplomat and Encourages Investors to Contact the Firm – GlobeNewswire” on March 27, 2019. More interesting news about Diplomat Pharmacy, Inc. (NYSE:DPLO) were released by: Globenewswire.com and their article: “CLASS ACTION UPDATE for BRS, DPLO, HCSG and INGN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders – GlobeNewswire” published on April 01, 2019 as well as Globenewswire.com‘s news article titled: “CLASS ACTION UPDATE for T, DPLO, UMC and MBT: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders – GlobeNewswire” with publication date: April 03, 2019.

Investors sentiment increased to 1.06 in 2018 Q4. Its up 0.05, from 1.01 in 2018Q3. It increased, as 26 investors sold DPLO shares while 42 reduced holdings. 19 funds opened positions while 53 raised stakes. 63.85 million shares or 3.37% more from 61.77 million shares in 2018Q3 were reported. Morgan Stanley, New York-based fund reported 105,034 shares. Ameriprise holds 0% of its portfolio in Diplomat Pharmacy, Inc. (NYSE:DPLO) for 322,902 shares. Oregon Public Employees Retirement Fund has 0.02% invested in Diplomat Pharmacy, Inc. (NYSE:DPLO) for 289,727 shares. Louisiana State Employees Retirement Systems holds 21,222 shares or 0.02% of its portfolio. Northern has invested 0% in Diplomat Pharmacy, Inc. (NYSE:DPLO). Old National Comml Bank In has invested 0.01% in Diplomat Pharmacy, Inc. (NYSE:DPLO). Pinebridge Invs Limited Partnership has 56,827 shares for 0.02% of their portfolio. Moreover, Mackay Shields Limited Company has 0.01% invested in Diplomat Pharmacy, Inc. (NYSE:DPLO) for 48,776 shares. 75,952 are owned by Engineers Gate Manager L P. Jefferies Group Inc Inc Ltd Limited Liability Company, New York-based fund reported 38,284 shares. First Interstate National Bank invested in 0% or 150 shares. 1.68M are held by Bancorporation Of Ny Mellon. Alphamark Advisors Lc holds 48,616 shares. Cubist Systematic Strategies Ltd Liability Corp stated it has 11,468 shares or 0.01% of all its holdings. State Street holds 0% or 1.90 million shares.

Diplomat Pharmacy, Inc. (NYSE:DPLO) Institutional Positions Chart


Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *